NMYC is overexpressed in both nervous system tumors (e.g., neuroblastoma, medulloblastoma, retinoblastoma, astrocytoma, and glioblastoma multiforme) and non-neuronal tumors (neuroendocrine prostate cancer, hematologic malignancies, and pancreatic tumors, among others). Here, MYCN is linked to neuroblastoma.